Meeting
2014 ASCO Annual Meeting
MAGNIFY: A phase 3B, randomized trial of lenalidomide plus rituximab induction and maintenance therapy followed by lenalidomide single-agent versus rituximab maintenance in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).
Authors
David J Andorsky
Rocky Mountain Cancer Centers, Boulder, CO
David J Andorsky , Patricia E Cataruozolo , Jorge L Mouro , Ju Li , Pierre Fustier , Kenneth A. Foon , Jeff Porter Sharman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01996865
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS8617)
DOI
10.1200/jco.2014.32.15_suppl.tps8617
Abstract #
TPS8617
Poster Bd #
301A
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
MAGNIFY: A randomized, phase 3b trial in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) investigating lenalidomide plus rituximab (R2) induction followed by maintenance R2 followed by lenalidomide versus R2 induction followed by rituximab (R) maintenance.
First Author: David Jacob Andorsky
Poster
2022 ASCO Annual Meeting
inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.
First Author: Laurie Helen Sehn
Poster
2018 ASCO Annual Meeting
Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.
First Author: David Andorsky
Poster
2024 ASCO Annual Meeting
Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
First Author: Umberto Vitolo